Dr. Hoffman-Censits

Jean Hoffman-Censits, MD

Contact Dr. Hoffman-Censits

925 Chestnut Street
Suite 220A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. A phase I/II study of the investigational drug alisertib in combination with abiraterone and prednisone for patientswithmetastatic castration-resistant prostate cancer progressing on abiraterone
  2. Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report
  3. Combination immunotherapy in genitourinary malignancies
  4. Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: Results of an investigator-initiated phase I-IIa clinical trial
  5. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial
  6. Systemic chemotherapy for upper tract urothelial cancer
  7. Perioperative and Maintenance Therapy after First-Line Therapy as Paradigms for Drug Discovery in Urothelial Carcinoma
  8. An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients
  9. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer
  10. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: Results of a multicenter phase II study with molecular correlates of response and toxicity
  11. Practical guide to the use of enzalutamide
  12. Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
  13. Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye
  14. Chemotherapy and targeted therapies: Are we making progress in castrate-resistant prostate cancer?
  15. Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: A report from the Bladder Cancer Advocacy Network Clinical Trials Working Group
  16. Enzalutamide: A novel antiandrogen for patients with castrate-resistant prostate cancer
  17. A wealth of new options: A case presentation of the management of castration-recurrent prostate cancer
  18. Physician beliefs and practices for adjuvant and salvage radiation therapy after prostatectomy
  19. Enhancing prostate cancer care through the multidisciplinary clinic approach: A 15-year experience
  20. Chemotherapy for Penile and Urethral Carcinoma